Clinical trials: Pulmonary Hypertension, Primary
Takayasu Arteritis With Pulmonary Artery Involvement, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
- Trial name
- CAPTAIN (NCT07184814)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension
The goal of this clinical study is to investigate whether the additional intake of sildenafil 20mg on top of standard medical treatment results in a benefit on maximum exercise workload (Wmax) in patients with pulmonary arterial…
- Trial name
- Pocket-PH (NCT07824674)
- Testing
- Dextrose, Sildenafil 20mg
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich
Primary and Secondary Pulmonary Hypertension
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
- Trial name
- NCT00155714
- Testing
- type-5 phosphodiesterase Inhibitor (Sildenafil)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension
Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
A multicenter, randomized, double-blind, placebo-controlled, phase II-III clinical trial to evaluate the efficacy and safety of the study drug in adult patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06683040
- Testing
- Oxacom
- Where
- Russia
- Volunteers
- 260 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Pulmonary Arterial Hypertension
Effects of DHEA in Pulmonary Hypertension
The goal of this crossover trial is to determine whether the study drug dehydroepiandrosterone (DHEA) improves right ventricular longitudinal strain measured by cardiac magnetic resonance imaging at 18 weeks AND 40 weeks compared…
- Trial name
- EDIPHY (NCT03648385)
- Testing
- DHEA tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rhode Island Hospital
Pulmonary Arterial Hypertension (PAH)
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their…
- Trial name
- NCT07177703
- Testing
- Treprostinil
- Volunteers
- 32 people
- Sponsor
- Shanghai Zhongshan Hospital
Hypertension, Pulmonary
Pulmonary Hypertension: Assessment of Cell Therapy
The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.
- Trial name
- PHACeT (NCT00469027)
- Testing
- eNOS transfected EPCs will be delivered via a PA line
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Northern Therapeutics
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
- Trial name
- NCT00159861
- Testing
- Sildenafil citrate
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension
Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic.
- Trial name
- NCT03401476
- Testing
- Morphine Sulfate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- John Granton
Pulmonary Idiopathic Arterial Hypertension
Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair. Current evidence established that endothelial progenitor cells (EPC) participate in several models of…
- Trial name
- NCT00551408
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Unidad de Investigacion Clinica en Medicina S.C.
Pulmonary Arterial Hypertension
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
Pulmonary arterial hypertension is a chronic disease of the lung blood vessels resulting in constriction and high pressures. Treatment is given with a variety of drugs including the prostanoid class (e.g.
- Trial name
- NCT00705588
- Testing
- Tadalafil, Vardenafil
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Pulmonary Hypertension
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass
Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of…
- Trial name
- MUSCLE UP-PH (NCT07132788)
- Testing
- blood draw, Short Performance Physical Battery, Grip strength test
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD
The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Ischemic Heart Disease
- Trial name
- NCT03780803
- Testing
- home cardiac rehabilitation and respiratory rehabilitation
- Where
- Poland
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Medical University of Bialystok
Hypertension, Pulmonary
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
This study is to investigate the efficacy, safety, and Pharmacokinetics (PK) of Inhaled Iloprost (Ventavis) therapy in Japanese pulmonary arterial hypertension (PAH) patients in Main Treatment Phase (12 weeks) and to investigate…
- Trial name
- IBUKI (NCT01469169)
- Testing
- Iloprost (Ventavis inhaled, BAYQ6256)
- Where
- 18 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
This study is designed to describe pulmonary arterial hypertension (PAH) participants in terms of their clinical characteristics, therapies used, disease progression, and outcomes (example, death, hospitalization, risk category…
- Trial name
- CARE PAH (NCT04955990)
- Testing
- PAH Therapies
- Where
- 54 sites in United States, Argentina and 15 more
- Volunteers
- 232 people
- Sponsor
- Actelion
Blood Pressure, Hypertension
Onco-primary Care Networking to Support TEAM-based Care
The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a…
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast
- Trial name
- ONE TEAM (NCT04258813)
- Testing
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- Duke University
Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH)
Safety and Effectiveness of a Virtual Pediatric Cardiac Rehabilitation Program or Telerehabilitation in Children With Heart Disease
Cardiac telerehabilitation is a much-needed pediatric therapy; however, a lack of randomized controlled trials has limited the development of and reimbursement for this valuable service.
- Conditions
- Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH), Orthotopic Heart Transplant, Cardiac Rehabilitation
- Trial name
- NCT06819059
- Testing
- Pediatric Cardiac Telerehabilitation, Fitness Tracker Only
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Pulmonary Arterial Hypertension
Efficacy of Ventavis Used in Real-life Setting.
This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis. Typical clinical measures and quality of life will be prospectively followed in 12 months period.
- Trial name
- SPHERA (NCT01355380)
- Testing
- Inhaled iloprost (Ventavis, BAYQ6256)
- Where
- Poland
- Volunteers
- 55 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
BAY63-2521 Riociguat leads to the relaxation of smooth muscle cells in pulmonary arteria and may also inhibit abnormal remodeling of lung blood vessels.
- Trial name
- RESPITE (NCT02007629)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Bayer